A Phase I Study of Safety and Immunogenicity of the WRAIR HIV-1 Vaccine

Inclusion Criteria: * Citizens of the U.S.A. who are not at high-risk for HIV infection. * Age: 18 through 45 years of age. * For women, negative serum pregnancy test will be required within two days prior to any injection, as well as verbal assurance that adequate contraceptive measures are applied. * Good health as determined by medical history, physical examination, and clinical judgment. Clinical laboratory values at screening within the following ranges: * Hematocrit: Women: \> 34%: Men \>38% (Mild anemia in any potential trial volunteer who is otherwise healthy attributable by appropriate laboratory studies to thalassemia minor will not be cause for exclusion) * White blood cell count: 3,000 to 12,000 cells/mm3 * Platelets: 125,000 to 550,000 per mm3 * Chemistry Panel: Expanded chemistry panel within institutional normal ranges or accompanied by site physician approval. * Urine dipstick for protein and blood: negative or trace. If either is ≥ 1+, obtain complete urinalysis (UA). If microscopic UA confirms evidence of hematuria or proteinuria ≥ 1+, the volunteer is ineligible unless menstruating, then a repeat UA is required. * Negative serology for HIV infection (ELISA test). * Availability for at least 52 weeks * Successful completion of the Test of Understanding, Commitment for Trial Participation and signature of the approved Trial Consent Form. Exclusion Criteria: * Acknowledge engaging in highest-risk behavior within 48 weeks of study entry: (i.e., active injecting drug use or having sexual intercourse with a known HIV-1 infected partner). * Have active tuberculosis or other systemic infectious process by review of systems and physical examination. * Have a history of immunodeficiency, chronic illness requiring continuous or frequent medical intervention, autoimmune disease, or use of immunosuppressive medications. * Have evidence of psychiatric, medical and/or substance abuse problems during the past 48 weeks that the investigator believes would adversely affect the volunteer's ability to participate in the trial. * Have occupational or other responsibilities that would prevent completion of participation in the study. * Have received any live, attenuated vaccine within 60 days of study entry. * NOTE: Medically indicated subunit or killed vaccines (e.g., Hepatitis A or Hepatitis B) are not exclusionary but should be given at least 2 weeks before or after HIV immunization to avoid potential confusion of adverse reactions. * Acute or chronic Hepatitis caused by viral or other etiology. * Have used experimental therapeutic agents within 30 days of study entry. * Have received blood products or immunoglobulins in the past 12 weeks. * Have a history of anaphylaxis or other serious adverse reactions to vaccines. * Have previously received an HIV and/or anthrax vaccine. * Currently enrolled in other vaccine trials. * Are pregnant or lactating. * NOTE: Women of child-bearing potential must be using effective contraception from the date of enrollment into the protocol. * Have an immediate type hypersensitivity reaction to aminoglyocides, e.g., kanamycin (used to prepare the LFn-p24 vaccine). * Are study site employees who are involved in the protocol and may have direct access to the immunogenicity results. * Are receiving ongoing therapy with immunosuppressive therapy such as systemic corticosteroids or cancer chemotherapy. * Are active duty military or reserves.